These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 17006963)

  • 41. Whose preferences count?
    Dolan P
    Med Decis Making; 1999; 19(4):482-6. PubMed ID: 10520686
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Collecting data on treatments for varicose veins: Getting the focus right.
    Campbell WB; Poole RL; Ray AF; Patrick HE
    Phlebology; 2017 May; 32(4):224-226. PubMed ID: 27329668
    [No Abstract]   [Full Text] [Related]  

  • 43. Modelling and estimation of valuations for the Dutch London Handicap Scale.
    Groothuis-Oudshoorn CG; Chorus AM; Taeke van Beekum W; Detmar SB; van den Hout WB
    J Health Econ; 2006 Nov; 25(6):1119-38. PubMed ID: 16516990
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public.
    Ubel PA; Loewenstein G; Jepson C
    Qual Life Res; 2003 Sep; 12(6):599-607. PubMed ID: 14516169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rationale for and measurement of patient preferences and health-related quality of life.
    Hillman BJ
    Acad Radiol; 1998 Sep; 5 Suppl 2():S277-9. PubMed ID: 9750831
    [No Abstract]   [Full Text] [Related]  

  • 46. Economics notes: handling uncertainty in economic evaluation.
    Briggs A
    BMJ; 1999 Jul; 319(7202):120. PubMed ID: 10398643
    [No Abstract]   [Full Text] [Related]  

  • 47. 'Should QALYs be programme specific?' by Donaldson, Atkinson, Bond and Wright.
    Williams A
    J Health Econ; 1989; 8(4):485-7; discussion 489-91. PubMed ID: 10296940
    [No Abstract]   [Full Text] [Related]  

  • 48. Whom should we ask? A systematic literature review of the arguments regarding the most accurate source of information for valuation of health states.
    Helgesson G; Ernstsson O; Åström M; Burström K
    Qual Life Res; 2020 Jun; 29(6):1465-1482. PubMed ID: 32016683
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of depression on health-related quality of life and wellbeing: identifying important dimensions and assessing their inclusion in multi-attribute utility instruments.
    Engel L; Chen G; Richardson J; Mihalopoulos C
    Qual Life Res; 2018 Nov; 27(11):2873-2884. PubMed ID: 30006664
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Experience-based utility and own health state valuation for a health state classification system: why and how to do it.
    Brazier J; Rowen D; Karimi M; Peasgood T; Tsuchiya A; Ratcliffe J
    Eur J Health Econ; 2018 Jul; 19(6):881-891. PubMed ID: 29022120
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Does diabetes have an impact on health-state utility? a study of Asians in Singapore.
    Wang P; Tai ES; Thumboo J; Vrijhoef HJ; Luo N
    Patient; 2014; 7(3):329-37. PubMed ID: 24756482
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using QALYs in cancer: a review of the methodological limitations.
    Garau M; Shah KK; Mason AR; Wang Q; Towse A; Drummond MF
    Pharmacoeconomics; 2011 Aug; 29(8):673-85. PubMed ID: 21599035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.
    Griebsch I; Coast J; Brown J
    Pediatrics; 2005 May; 115(5):e600-14. PubMed ID: 15867026
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness analysis of surgery versus conservative treatment for uncomplicated varicose veins in a randomized clinical trial.
    Ratcliffe J; Brazier JE; Campbell WB; Palfreyman S; MacIntyre JB; Michaels JA
    Br J Surg; 2006 Feb; 93(2):182-6. PubMed ID: 16432810
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A comparison of patient and population values for health states in varicose veins patients.
    Ratcliffe J; Brazier J; Palfreyman S; Michaels J
    Health Econ; 2007 Apr; 16(4):395-405. PubMed ID: 17006963
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cost-effectiveness analysis: role and implications.
    Marsden G; Wonderling D
    Phlebology; 2013 Mar; 28 Suppl 1():135-40. PubMed ID: 23482549
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population.
    Mulhern B; Rowen D; Snape D; Jacoby A; Marson T; Hughes D; Baker G; Brazier J
    Epilepsy Behav; 2014 Jul; 36():12-7. PubMed ID: 24836527
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.